| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3,810.0 | 3,563.5 |
| Gross profit | 1,108.1 | 1,025.1 |
| Net income | 262.8 | 261.1 |
| EPS (diluted, $ a share) | $3.22 | $3.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +0.7% |
|---|---|
| Revenue, year on year | +6.9% |
| Gross margin | 29.1% |
| Operating margin | 10.6% |
10-Q filed with the SEC, NYSE: LH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Labcorp Holdings Inc.: key numbers
- Share price
- $372.46Close, Nov 16
- Market cap
- $30.2B
- Shares outstanding
- 81.2MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Labcorp Holdings Inc.
All →Labcorp Holdings EVP, Pres of BLS, CMO & CSO Brian J. Caveney Sells $744K of Stock
Brian J. Caveney, EVP, Pres of BLS, CMO & CSO, sold 2,000 shares of Labcorp Holdings Inc. at $372.04 a share, worth $744K in total on Nov 10, 2026. Shares held after the trade: 34,562 (-5.5%).
- Value
- $744K
- Shares
- 2,000
- Price
- $372.04
- Role
- EVP, Pres of BLS, CMO & CSO
- Holding change
- -5.5%
- Trade date
- Nov 10, 2026
Labcorp Holdings EVP and President, Diagnostics Bryan T. Vaughn Sells $108K of Stock
Bryan T. Vaughn, EVP and President, Diagnostics, sold 306 shares of Labcorp Holdings Inc. at $353.70 a share, worth $108K in total on Nov 3, 2026. Shares held after the trade: 6,845 (-4.3%).
- Value
- $108K
- Shares
- 306
- Price
- $353.70
- Role
- EVP and President, Diagnostics
- Holding change
- -4.3%
- Trade date
- Nov 3, 2026
Labcorp Holdings Investor Presentation
Labcorp Holdings Inc. announced that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026. The event will feature a fireside chat and a live audio webcast will be available through the company's investor relations website.
Labcorp Holdings Insider Richelle P. Parham Sells $389K of Stock
Richelle P. Parham sold 1,078 shares of Labcorp Holdings Inc. at $361.22 a share, worth $389K in total on Oct 30, 2026. Shares held after the trade: 2,288 (-32.0%).
- Value
- $389K
- Shares
- 1,078
- Price
- $361.22
- Holding change
- -32.0%
- Trade date
- Oct 30, 2026
Labcorp Holdings Financial Results
Labcorp reported third quarter 2026 revenue of $3.81 billion, a 6.9% increase year-over-year, driven by strong performance in specialty testing and strategic acquisitions. The company raised its full-year 2026 adjusted EPS guidance to a range of $18.30 to $18.70 and highlighted the FDA approval of its PGDx elio tissue complete CDx as a companion diagnostic for melanoma.
- Term
- Q3 2026
“Labcorp delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our full-year guidance. We furthered our leadership in specialty testing by launching innovative tests for advanced melanoma, Alzheimer’s disease, and hepatitis D, while expanding access through strategic acquisitions across our Diagnostics and Biopharma Laboratory Services businesses.”
Adam Schechter, Chairman and CEO of Labcorp
Labcorp Holdings Dividend
Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on December 11, 2026, to stockholders of record as of November 24, 2026.